Vericel (NASDAQ:VCEL – Get Free Report) and Compass Therapeutics (NASDAQ:CMPX – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings and profitability.
Valuation and Earnings
This table compares Vericel and Compass Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vericel | $276.26 million | 7.02 | $16.52 million | $0.47 | 80.57 |
| Compass Therapeutics | $850,000.00 | 434.33 | -$66.49 million | ($0.40) | -5.12 |
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Vericel and Compass Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vericel | 0 | 3 | 4 | 0 | 2.57 |
| Compass Therapeutics | 1 | 1 | 13 | 1 | 2.88 |
Vericel presently has a consensus price target of $58.40, suggesting a potential upside of 54.21%. Compass Therapeutics has a consensus price target of $11.77, suggesting a potential upside of 474.11%. Given Compass Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Compass Therapeutics is more favorable than Vericel.
Risk & Volatility
Vericel has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500.
Profitability
This table compares Vericel and Compass Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vericel | 7.91% | 6.91% | 5.02% |
| Compass Therapeutics | N/A | -38.71% | -34.72% |
Insider and Institutional Ownership
68.4% of Compass Therapeutics shares are held by institutional investors. 7.6% of Vericel shares are held by insiders. Comparatively, 18.7% of Compass Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Vericel beats Compass Therapeutics on 8 of the 15 factors compared between the two stocks.
About Vericel
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
About Compass Therapeutics
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.
